Last updated on August 2019

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Brief description of study

This is a randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.

Clinical Study Identifier: NCT03669588

Find a site near you

Start Over

Investigator Site 42

Chiba-shi, Japan
  Connect »